The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

Science Translational Medicine

Volumn 7, Issue 270, 2015, Pages

  Radzio, Jessica ^a   Spreen, William ^b   Yueh, Yun Lan ^b   Mitchell, James ^a   Jenkins, Leecresia ^a   García Lerma, J Gerardo ^a   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOTEGRAVIR; INTEGRASE INHIBITOR; LONG ACTING DRUG; PLACEBO; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG COMBINATION; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ORGANOPHOSPHORUS COMPOUND; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; ELIMINATION HALF-LIFE; FEMALE; MACACA NEMESTRINA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VAGINAL SECRETION; VIRUS TRANSMISSION; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; IC50; INTRAVAGINAL DRUG ADMINISTRATION; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VIROLOGY;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INHIBITORY CONCENTRATION 50; INTEGRASE INHIBITORS; MACACA; ORGANOPHOSPHORUS COMPOUNDS; PYRIDONES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

EID: 84921044609     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010297     Document Type: Article

References (24)

1. UNAIDS report on the global AIDS epidemic 2013, http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf.
2. J. M. Baeten, D. Donnell, P. Ndase, N. R. Mugo, J. D. Campbell, J. Wangisi, J. W. Tappero, E. A. Bukusi, C. R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K. H. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira, D. Panteleeff, K. K. Thomas, L. Kidoguchi, M. Krows, J. Revall, S. Morrison, H. Haugen, M. Emmanuel-Ogier, L. Ondrejcek, R. W. Coombs, L. Frenkel, C. Hendrix, N. N. Bumpus, D. Bangsberg, J. E. Haberer, W. S. Stevens, J. R. Lingappa, C. Celum; Partners PrEP Study Team, Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399-410 (2012).
3. R. M. Grant, J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, M. Casapía, J. V. Guanira-Carranza, M. E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernández, V. G. Veloso, S. P. Buchbinder, S. Chariyalertsak, M. Schechter, L. G. Bekker, K. H. Mayer, E. G. Kallás, K. R. Amico, K. Mulligan, L. R. Bushman, R. J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J. J. McConnell, J. H. Zheng, J. Lee, J. F. Rooney, H. S. Jaffe, A. I. Martinez, D. N. Burns, D. V. Glidden; iPrEx Study Team, Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
4. M. C. Thigpen, P. M. Kebaabetswe, L. A. Paxton, D. K. Smith, C. E. Rose, T. M. Segolodi, F. L. Henderson, S. R. Pathak, F. A. Soud, K. L. Chillag, R. Mutanhaurwa, L. I. Chirwa, M. Kasonde, D. Abebe, E. Buliva, R. J. Gvetadze, S. Johnson, T. Sukalac, V. T. Thomas, C. Hart, J. A. Johnson, C. K. Malotte, C. W. Hendrix, J. T. Brooks; TDF2 Study Group, Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423-434 (2012).
5. L. Van Damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard, S. Kapiga, M. Malahleha, F. Owino, R. Manongi, J. Onyango, L. Temu, M. C. Monedi, P. Mak ' Oketch, M. Makanda, I. Reblin, S. E. Makatu, L. Saylor, H. Kiernan, S. Kirkendale, C. Wong, R. Grant, A. Kashuba, K. Nanda, J. Mandala, K. Fransen, J. Deese, T. Crucitti, T. D. Mastro, D. Taylor; FEM-PrEP Study Group, Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012).
6. J. Marrazzo, G. Ramjee, G. Nair, T. Palanee, B. Mkhize, C. Nakabiito, M. Taljaard, J. Piper, K. Gomez Feliciano, M. Chirenje; VOICE study team, Preexposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003), Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013.
7. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A. C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; CAPRISA 004 Trial Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
8. R. M. Grant, P. L. Anderson, V. McMahan, A. Liu, K. R. Amico, M. Mehrotra, S. Hosek, C. Mosquera, M. Casapia, O. Montoya, S. Buchbinder, V. G. Veloso, K. Mayer, S. Chariyalertsak, L. G. Bekker, E. G. Kallas, M. Schechter, J. Guanira, L. Bushman, D. N. Burns, J. F. Rooney, D. V. Glidden; iPrEx study team, Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect. Dis. 14, 820-829 (2014).
9. C. W. Geary, E. A. Bukusi, Women and ARV-based HIV prevention-Challenges and opportunities. J. Int. AIDS Soc. 17 (Suppl. 2), 19356 (2014).
10. N. Mack, E. M. Evens, E. E. Tolley, K. Brelsford, C. Mackenzie, C. Milford, J. A. Smit, J. Kimani, The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: A qualitative study. J. Int. AIDS Soc. 17 (Suppl. 2), 19157 (2014).
11. J. M. Smith, R. Rastogi, R. S. Teller, P. Srinivasan, P. M. Mesquita, U. Nagaraja, J. M. McNicholl, R. M. Hendry, C. T. Dinh, A. Martin, B. C. Herold, P. F. Kiser, Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc. Natl. Acad. Sci. U.S.A. 110, 16145-16150 (2013).
12. J. Romano, B. Variano, P. Coplan, J. Van Roey, K. Douville, Z. Rosenberg, M. Temmerman, H. Verstraelen, L. Van Bortel, S. Weyers, M. Mitchnick, Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25, 483-488 (2009).
13. C. D. Andrews, W. R. Spreen, H. Mohri, L. Moss, S. Ford, A. Gettie, K. Russell-Lodrigue, R. P. Bohm, C. Cheng-Mayer, Z. Hong, M. Markowitz, D. D. Ho, Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343, 1151-1154 (2014).
14. W. R. Spreen, D. A. Margolis, J. C. Pottage Jr., Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV AIDS 8, 565-571 (2013).
15. A. G. Jackson, L. J. Else, P. M. Mesquita, D. Egan, D. J. Back, Z. Karolia, L. Ringner-Nackter, C. J. Higgs, B. C. Herold, B. G. Gazzard, M. Boffito, A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin. Pharmacol. Ther. 96, 314-323 (2014).
16. W. Spreen, P. Williams, D. Margolis, S. L. Ford, H. Crauwels, Y. Lou, E. Gould, M. Stevens, S. Piscitelli, Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J. Acquir. Immune Defic. Syndr. 67, 487-492 (2014).
17. W. Spreen, S. L. Ford, S. Chen, D. Wilfret, D. Margolis, E. Gould, S. Piscitelli, GSK1265744 pharmacokinetics in plasma and tissue after single-dose Long-acting injectable administration in healthy subjects. J. Acquir. Immune Defic. Syndr. 67, 481-486 (2014).
18. R. A. Otten, D. R. Adams, C. N. Kim, E. Jackson, J. K. Pullium, K. Lee, L. A. Grohskopf, M. Monsour, S. Butera, T. M. Folks, Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 191, 164-173 (2005).
19. J. Radzio, W. Aung, A. Holder, A. Martin, E. Sweeney, J. Mitchell, S. Bachman, C. P. Pau, W. Heneine, J. G. García-Lerma, Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLOS One 7, e50632 (2012).
20. C. D. Andrews, Y. L. Yueh, W. R. Spreen, L. St. Bernard, M. Boente-Carrera, K. Rodriguez, A. Gettie, K. Russell-Lodrigue, J. Blanchard, S. Ford, H. Mohri, C. Cheng-Mayer, Z. Hong, D. D. Ho, M. Markowitz, A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra4 (2015).
21. J. Mordenti, Man versus beast: Pharmacokinetic scaling in mammals. J. Pharm. Sci. 75, 1028-1040 (1986).
22. B. N. Greener, K. B. Patterson, H. M. Prince, C. S. Sykes, J. L. Adams, J. B. Dumond, N. J. Shaheen, R. D. Madanick, E. S. Dellon, M. S. Cohen, A. D. Kashuba, Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J. Acquir. Immune Defic. Syndr. 64, 39-44 (2013).
23. T. R. Henning, K. Butler, D. Hanson, G. Sturdevant, S. Ellis, E. M. Sweeney, J. Mitchell, F. Deyounks, C. Phillips, C. Farshy, Y. Fakile, J. Papp, W. Evan Secor, H. Caldwell, D. Patton, J. M. McNicholl, E. Kersh, Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis. J. Infect. Dis. 210, 1239-1247 (2014).
24. J. G. García-Lerma, M. E. Cong, J. Mitchell, A. S. Youngpairoj, Q. Zheng, S. Masciotra, A. Martin, Z. Kuklenyik, A. Holder, J. Lipscomnb, C. P. Pau, J. R. Barr, D. L. Hanson, R. Otten, L. Paxton, T. M. Folks, W. Heneine, Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2, 14ra4 (2010).